Lauren M Sabella
CIK 1360928 · EVP Operations · last filed 2025-07-17
Lauren M Sabella is an EVP Operations who has filed 49 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing shows the insider had shares withheld for taxes covering $45.8K of MNKD on Jul 17, 2025. Across all open-market trades the lifetime net is −$3.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACOR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
420 SAW MILL RIVER ROAD
ARDSLEY, NY 10502
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MNKD | EVP Operations | 349,841 | $3.14 | $1.10M | $0 | 9 | 2025-07-17 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | Chief Operating Officer | 536 | $0.66 | $354 | -$3.93M | 38 | 2022-09-07 |
| Altus Pharmaceuticals Inc. (ALTU) Delisted | VP of Commercial Development | — | $10.12 | — | $0 | 2 | 2008-02-27 |
Recent Filings
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-17 | MNKD | Tax (F) | −11,896 | -$45.8K | EDGAR |
| 2025-03-28 | MNKD | Tax (F) | −16,407 | -$83.7K | EDGAR |
| 2024-07-17 | MNKD | Mixed | −1,095 | -$8.4K | EDGAR |
| 2024-05-17 | MNKD | Grant (A) | +129,000 | $0 | EDGAR |
| 2024-03-29 | MNKD | Tax (F) | −17,084 | -$79.1K | EDGAR |
| 2024-02-05 | MNKD | Grant (A) | +16,001 | $52.2K | EDGAR |
| 2023-05-26 | MNKD | Grant (A) | +23,250 | $0 | EDGAR |
| 2023-05-24 | MNKD | Grant (A) | +210,000 | $0 | EDGAR |
| 2023-05-15 | MNKD | Grant (A) | +14,184 | $60.0K | EDGAR |
| 2022-09-07 | Acorda Therapeutics, Inc. (ACOR) Delisted | Tax (F) | −1,511 | -$601 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.